Cargando…
Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effect...
Autores principales: | Zarogoulidis, Paul, Huang, Haidong, Tsiouda, Theodora, Sardeli, Chrysa, Trakada, Georgia, Veletza, Lemonia, Kallianos, Anastasios, Kosmidis, Christoforos, Rapti, Aggeliki, Papaemmanouil, Liana, Hatzibougias, Dimitrios, Drougas, Dimitrios, Bai, Chong, Hohenforst-Schmidt, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671388/ https://www.ncbi.nlm.nih.gov/pubmed/29124007 http://dx.doi.org/10.1016/j.rmcr.2017.10.006 |
Ejemplares similares
-
Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)